 NEEDHAM, Mass., Aug. 17, 2021 GLOBE NEWSWIRE -- Candel Therapeutics, Inc. Candel, a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced the closing of the issuance of an additional 887,994 shares of its common stock at a public offering price of 8.00 per share. The shares were issued pursuant to a partial exercise of the underwriters option to purchase additional shares of common stock in connection with Candels previously announced initial public offering of 9,000,000 shares of its common stock. The gross proceeds from the exercise of the option to purchase additional shares were approximately 7.1 million, bringing the aggregate gross proceeds to Candel from its initial public offering to approximately 79.1 million, before deducting underwriting discounts and commissions and other offering expenses. 